Changeflow GovPing Healthcare & Life Sciences First Imported Human Case Avian Influenza A(H9N...
Routine Notice Added Final

First Imported Human Case Avian Influenza A(H9N2) Italy Senegal Origin

Favicon for www.who.int WHO Disease Outbreak News
Published
Detected
Email

Summary

Italy's National IHR Focal Point notified WHO on 21 March 2026 of a human case of avian influenza A(H9N2) in an adult male who had resided in Senegal for more than six months before traveling to Italy in mid-March. Next-generation sequencing confirmed the H9N2 subtype, with genetic analysis showing close similarity to strains previously identified in poultry in Senegal. This is the first imported human case of avian Influenza A(H9N2) reported in the European Region. No direct animal exposure was identified, and all traced contacts in Italy tested negative. WHO assesses the current risk to the general population as low.

“This is the first imported human case of avian Influenza A(H9N2) reported in the European Region.”

WHO , verbatim from source
Published by WHO on who.int . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors WHO Disease Outbreak News for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 3 changes logged to date.

What changed

This WHO Disease Outbreak News reports the first imported human case of avian Influenza A(H9N2) in the European Region, identified in an adult male returning from Senegal to Italy. The patient had been in Senegal for over six months with no identified direct animal exposure; genetic sequencing confirmed close similarity to poultry strains from Senegal. Italy implemented contact tracing, negative-pressure isolation, and active monitoring of contacts, all of whom tested negative. WHO advises against travel or trade restrictions and recommends avoiding contact with high-risk environments such as live animal markets, with respiratory protection for those handling poultry.

For public health authorities and healthcare providers, this case demonstrates the ongoing risk of novel influenza subtype importation through international travel from endemic areas. Under IHR Article 6, all human infections caused by a new influenza virus subtype must be notified to WHO. Laboratories and surveillance systems should maintain vigilance for unsubtypeable influenza A detections, particularly in patients with recent travel to countries where H9N2 circulates in poultry.

Archived snapshot

Apr 23, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

Disease Outbreak News

Avian Influenza A(H9N2) - Italy

10 April 2026
See all DONs related to this event

Situation at a glance

On 21 March 2026, the National International Health Regulations (IHR) Focal Point for Italy notified the World Health Organization (WHO) of the identification of a human case of avian influenza A(H9) in an adult male returning from Senegal. Next generation sequencing confirmed Influenza A(H9N2). According to epidemiological investigations, the patient had no known history of exposure to poultry or any person with similar symptoms prior to the onset of symptoms. Authorities in Italy have implemented a series of measures aimed at monitoring, preventing and controlling the situation. According to the IHR (2005), a human infection caused by a novel influenza A virus subtype is an event that has the potential for high public health impact and must be notified to the WHO. This is the first imported human case of avian Influenza A(H9N2) reported in the European Region. Based on currently available information, WHO assesses the current risk to the general population posed by A(H9N2) viruses as low but continues to monitor these viruses and the situation globally.

Description of the situation

On 21 March 2026, the National IHR Focal Point for Italy notified WHO of the identification of a human case of avian influenza A(H9) in an adult male.

The patient had been in Senegal for more than six months and traveled to Italy in mid-March. Upon arrival, he visited the emergency department with a fever and a persistent cough.

On 16 March, a bronchoalveolar lavage specimen was collected, which showed a positive Mycobacterium tuberculosis result, as well as detection of un-subtypeable influenza A virus. The patient was placed in a negative-pressure isolation room with airborne precautions. He was treated with antitubercular medication and antiviral oseltamivir. By 9 April, his condition was stable and improving.

On 20 March, a regional reference laboratory identified the A(H9) subtype, and on 21 March, next-generation sequencing confirmed influenza A(H9N2). Initial genetic findings suggest the infection was likely acquired from an avian source linked to Senegal. Additional samples have been sent to Italy’s National Influenza Center, where further characterization confirmed virus subtype Influenza A(H9N2), with close genetic similarity to strains previously identified in poultry in Senegal.

No direct exposure to animals, wildlife or rural environments was identified. There was also no reported contact with symptomatic or confirmed human cases. Further epidemiological investigations on the source of exposure are ongoing.

Contacts identified in Senegal were asymptomatic. All identified and traced contacts in Italy have tested negative for influenza and completed the period of active monitoring for the onset of symptoms and the quarantine required by national guidelines. They also received oseltamivir as a preventive measure.

Epidemiology

Animal influenza viruses normally circulate in animals but can also infect people. Infections in humans have primarily been acquired through direct contact with infected animals or through indirect contact with contaminated environments. Depending on the original host, influenza A viruses can be classified as avian influenza, swine influenza, or other types of animal influenza viruses.

Avian influenza virus infections in humans may cause diseases ranging from mild upper respiratory tract infection to more severe diseases and can be fatal. Conjunctivitis, gastrointestinal symptoms, encephalitis and encephalopathy have also been reported.

Laboratory tests are required to diagnose human infection with influenza. WHO periodically updates technical guidance protocols for the detection of zoonotic influenza using molecular methods.

Human infections with influenza A(H9) viruses have been reported from countries in Africa and Asia, where these viruses are also detected in poultry. The majority of cases of human avian influenza A(H9N2) infection have been reported from China. This is the first imported human case of avian Influenza A(H9N2) virus infection reported in the European Region.

Public health response

Contact tracing procedures have been initiated, and relevant authorities in Italy, as well as internationally (National IHR Focal Point for Senegal, WHO, and European Centre for Disease Prevention and Control (ECDC)) have been informed through IHR channels. Once avian influenza was suspected, the response moved quickly from hospital-level management to regional laboratory confirmation and national coordination. Additionally, the regional surveillance system was notified, integrated within the One Health avian influenza reporting framework.

WHO risk assessment

Most reported human cases of A(H9N2) virus infection have been linked to exposure to infected poultry or contaminated environments, with the majority of cases experiencing mild clinical illness. Sporadic human cases following exposure to infected birds or contaminated environments can be expected since the virus remains enzootic in poultry populations. Avian influenza A(H9N2) viruses have been detected in poultry and environmental samples collected at live bird markets in Senegal and authorities in the country reported a human case of infection with an A(H9N2) virus in 2020.

Current epidemiological and virological evidence indicates that none of the characterized influenza A(H9N2) viruses thus far have acquired the ability for sustained transmission among humans. Thus, the likelihood of sustained human-to-human spread is low at this time. Infected individuals traveling internationally from affected areas may be identified in another country during or after arrival. However, if this were to occur, further community-level spread is considered unlikely. The risk assessment would be revisited if and when further epidemiological and virological information becomes available.

WHO advice

This case does not change the current WHO recommendations on public health measures and surveillance of influenza.

The public should avoid contact with high-risk environments such as live animal markets/farms or surfaces that might be contaminated by poultry feces. Respiratory protection is highly recommended for those handling live or dead (including slaughtering) poultry in occupational or backyard-farming settings. Good hand hygiene, i.e. frequent washing of hands or the use of alcohol-based hand sanitizer is recommended. WHO does not recommend any specific additional measures for travelers.

Under Article 6 of the IHR, all human infections caused by a new subtype of influenza virus are notifiable. The case definition for notification of human influenza infection caused by a new subtype under the IHR is provided here. State Parties to the IHR are required to immediately notify WHO of any laboratory-confirmed case of a human infection caused by such an influenza A virus.

WHO advises against the application of any travel or trade restrictions based on the current information available on this event.

Further information

Get daily alerts for WHO Disease Outbreak News

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from WHO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
WHO
Published
April 10th, 2026
Instrument
Notice
Branch
International
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
DON597

Who this affects

Applies to
Public health authorities Healthcare providers
Industry sector
6211 Healthcare Providers
Activity scope
Disease outbreak surveillance Influenza monitoring
Geographic scope
European Union EU

Taxonomy

Primary area
Public Health
Operational domain
Clinical Operations
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when WHO Disease Outbreak News publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!